Trial
NCT00439634
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sanofi
Collaborators
—
Condition
Schizophrenia
Intervention
AVE1625
Why stopped
Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to insufficient level of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-18